NCT06072339

Brief Summary

This is an open-label, randomized controlled study comparing two non-invasive ventilation initiation strategies.Patients may be included if they present with acute respiratory failure related to blunt chest trauma.The intervention group will benefit from the use by the physiotherapist of pulmonary ultrasound for the adjustment of Positive End Expiratory Pressure (PEEP) during the 1st session. The conventional group will benefit from the non-invasive ventilation according to the current care.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 2, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 10, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

December 19, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 19, 2025

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 26, 2025

Completed
Last Updated

October 4, 2024

Status Verified

October 1, 2024

Enrollment Period

2 years

First QC Date

October 2, 2023

Last Update Submit

October 2, 2024

Conditions

Keywords

thoracic injuriesnon-invasive ventilationPositive End Expiratory PressureUltrasonography

Outcome Measures

Primary Outcomes (1)

  • PaO2/FiO2 ratio (Arterial oxygen pressure / inspired oxygen fraction) in both groups

    PaO2/FiO2 ratio (Arterial oxygen pressure / inspired oxygen fraction) in both groups. This PaO2/FiO2 ratio is now the benchmark for qualifying the severity of the respiratory impairment or measuring the response to a mechanical ventilation strategy aimed at improving oxygenation.

    at the 30th minute from the start of the 1st Non-invasive ventilation session

Secondary Outcomes (9)

  • Comparaison of the Lung Ultrasound Score (LUS) in both groups

    at the 30th minute from the start of the 1st Non-invasive ventilation session

  • Comparaison of the PEEP value set at the start of the non-invasive ventilation session

    At the start of the non-invasive ventilation session

  • Comparaison of the confort value in both groups

    at the 30th minute from the start of the 1st Non-invasive ventilation session

  • Comparaison of the pain value in both groups

    at the 30th minute from the start of the 1st Non-invasive ventilation session

  • Comparaison of the PaO2/FiO2 ratio in both groups

    1 hour after the end of the 1st non-invasive ventilation session

  • +4 more secondary outcomes

Study Arms (2)

Experimental

EXPERIMENTAL

The intervention group will benefit from the physiotherapist's use of lung ultrasound for the PEEP adjustment during the first NIV session.

Other: Lung Ultrasound for PEEP settingProcedure: Non invasive ventilation sessionBiological: Arterial blood gasOther: Interview on pain and comfort

Control

ACTIVE COMPARATOR

The conventional group will benefit from the NIV under the current terms.

Procedure: Non invasive ventilation sessionBiological: Arterial blood gasOther: Interview on pain and comfort

Interventions

NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.

Experimental

The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece. The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.

ControlExperimental

Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.

ControlExperimental

The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).

ControlExperimental

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18 or more
  • Admitted to intensive care or continuing care for 72 hours or less for blunt chest trauma, defined by the presence of at least one of the following elements on the initial CT scan: fracture(s) of rib(s) / fracture(s) of the sternum / pulmonary contusion / hemothorax
  • Acute hypoxemic respiratory failure defined by the administration of oxygen at least 3 L/min with nasal cannula or FiO2≥30% if high flow oxygen therapy.
  • Patient with a functional arterial catheter for blood tests

You may not qualify if:

  • Acute respiratory distress, defined by the presence of at least one of the following clinical signs: respiratory rate ˃ 35 / use of accessory inspirators / paradoxal abdominal or thoracic motion
  • Imminent need for invasive mechanical ventilation
  • Usual contraindication to non-invasive ventilation (undrained pneumothorax, trauma to the face, vigilance disorders, digestive bleeding, hemodynamic instability, intolerance)
  • Hypercapnia (PaCO2˃45mmHg)
  • Patient unable to cooperate, communicate
  • Therapeutic limitation
  • Expected length of stay ≤ 48h
  • Severe head trauma
  • Pregnant or breastfeeding women
  • Participation in other clinical research related to respiratory failure/respiratory therapy
  • Vulnerable people
  • Protected adults, under guardianship or curatorship, or unable to give consent
  • Non-affiliated person or beneficiary of a social security scheme
  • Absence of free, informed and written consent, signed by the participant and the investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UH of Montpellier

Montpellier, 34295, France

RECRUITING

MeSH Terms

Conditions

Thoracic Injuries

Interventions

Blood Gas Analysismethyl hydroxyethyl cellulose

Condition Hierarchy (Ancestors)

Wounds and Injuries

Intervention Hierarchy (Ancestors)

Blood Chemical AnalysisClinical Chemistry TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisRespiratory Function TestsDiagnostic Techniques, Respiratory SystemInvestigative Techniques

Central Study Contacts

David CHAPEAU, Physiotherapist

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: open-labeled, controlled, randomized study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 2, 2023

First Posted

October 10, 2023

Study Start

December 19, 2023

Primary Completion

December 19, 2025

Study Completion

December 26, 2025

Last Updated

October 4, 2024

Record last verified: 2024-10

Locations